Company intelligence / Profile preview

Serinus Biosciences

New York, New York, United Statesserinus.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

No clinical results published yet; company claims its AI-driven approach can rapidly generate effective drug combinations to overcome cancer resistance and expand patient eligibility for targeted therapies. Pipeline could impact over 100,000 patients per year if successful.[2]

Therapeutic areas: Oncology
Modalities: Small moleculesCombination therapies (AI-designed drug combinations)[2][5]
Industry: Biotech

Partnerships

Seeking co-development partners; none announced

Beyond the preview

Go deeper on Serinus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serinus Biosciences.

Explore the full profile